Stock Information
Allogene Therapeutics Inc (ALLO)
Ticker Symbol: ALLO
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $557.33 mil
Piotroski score: 2
PE Ratio: N/A
EPS (TTM): -0.8683
Revenue (TTM): $0.00 M
Dividend Yield: N/A%
ROE: -57.07%
Latest News
-
Get insights into the top gainers and losers of Friday's after-hours session.
Fri, Apr 10, 2026 9:00 PM
-
12 Health Care Stocks Moving In Friday's After-Market Session
Fri, Apr 10, 2026 5:13 PM
-
Allogene Therapeutics shares are trading higher after the company announced Monday's webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel in first-line consolidation large B-cell lymphoma.
Fri, Apr 10, 2026 4:26 PM
-
Allogene Therapeutics To Present Interim Futility Analysis From Its Pivotal Phase 2 ALPHA3 Study With Cemacabtagene Ansegedleucel In First-Line Consolidation Large B-Cell Lymphoma On April 13
Fri, Apr 10, 2026 4:05 PM
Key Financials
Financial data not available
